The Effects of Repetitive Transcranial Magnetic Stimulation on Anxiety in Patients With Moderate to Severe Traumatic Brain Injury: A Post-hoc Analysis of a Randomized Clinical Trial.

Related Articles:

• The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
• 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…
• Journey With Parkinson’s: (Part 2) A Different Side of Life November 2, 2020 “Yesterday is but today’s memory, and tomorrow is today’s dream.” Khalil Gibran “Time is free, but it’s priceless. You can’t own it, but you can use it. You can’t keep it, but you can spend it. Once you’ve lost it you can never get it back.” Harvey Mackay Introduction: I am a scientist, trained as a protein chemist with expertise…
• Journey With Parkinson’s: (Part 2) A Different Side of Life November 2, 2020 “Yesterday is but today’s memory, and tomorrow is today’s dream.” Khalil Gibran “Time is free, but it’s priceless. You can’t own it, but you can use it. You can’t keep it, but you can spend it. Once you’ve lost it you can never get it back.” Harvey Mackay Introduction: I am a scientist, trained as a protein chemist with expertise…
• Monthly Research Review – November 2020 November 30, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
• Monthly Research Review – December 2020 December 31, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
• Monthly research review: February 2020 February 29, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• 2019: Year in review December 31, 2019   In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2019. Month-by-month we will briefly discuss some of the major pieces of research/announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies to any researchers who…
• Monthly Research Review: Jaunary 2020 January 31, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during January 2020. The post is divided into seven parts based on the type of research: Basic biology, Disease mechanism, Clinical research, New clinical trials, Clinical trial news, Other news, and…
• Shining a light on Parkinson’s November 7, 2019   NOTE: The information in today’s post should not be considered an endorsement of PhotoPharmics or the treatment they are proposing. The author of this blog has had no communication with the company. The information in this post is provided because the author has been asked by readers to discuss it. In October 2018, at the annual International Movement Disorders…
• Life with Parkinson’s in the Time of COVID-19: April is Parkinson’s Awareness Month April 1, 2020 “The measure of who we are is what we do with what we have.” Vince Lombardi “When you have exhausted all possibilities, remember this: you haven’t.” Thomas Edison Précis: A different world exists today than it did just a few weeks ago, all driven by the COVID-19 pandemic. The virus seemingly favors the elderly who have a pre-existing disease(s); however,…
• ALS: From ice bucket to centaur November 18, 2020 # # # # Amyotrophic lateral sclerosis (or ALS) is the third most common neurodegenerative condition. It is characterised by the loss of motor neurons, which leads to loss of muscle control. As with Parkinson’s, there is no cure for ALS, and there are only two FDA approved therapies for the condition. Recently, a biotech company – called Amylyx Pharmaceuticals…
• Life with Parkinson’s in the Time of COVID-19: April is Parkinson’s Awareness Month April 1, 2020 “The measure of who we are is what we do with what we have.” Vince Lombardi “When you have exhausted all possibilities, remember this: you haven’t.” Thomas Edison Précis: A different world exists today than it did just a few weeks ago, all driven by the COVID-19 pandemic. The virus seemingly favors the elderly who have a pre-existing disease(s); however,…
• AAN 2019 Plenary Session Highlights Research With Implications for Patient Care From Multiple Society Meetings May 9, 2019 The following article is part of conference coverage from the 2019 American Academy of Neurology Annual Meeting (AAN 2019) in Philadelphia, PA. Neurology Advisor’s staff will be reporting breaking news associated with research conducted by leading experts in neurology. Check back for the latest news from AAN 2019. PHILADELPHIA – A plenary session at the 2019 American Academy of Neurology…
• Journey with Parkinson’s: (Part 1) Another Side of Life October 27, 2020 “All we have to decide is what to do with the time that is given us.” J. R. R. Tolkien “We must not allow the clock and the calendar to blind us to the fact that each moment of life is a miracle and mystery.” H. G. Wells Introduction:  Parkinson’s changes us in many ways: it makes us stronger by…
• Journey with Parkinson’s: (Part 1) Another Side of Life October 27, 2020 “All we have to decide is what to do with the time that is given us.” J. R. R. Tolkien “We must not allow the clock and the calendar to blind us to the fact that each moment of life is a miracle and mystery.” H. G. Wells Introduction:  Parkinson’s changes us in many ways: it makes us stronger by…
• The drug development pipeline for Parkinson’s December 2, 2020 # # # # For a long time a regular request from SoPD readers has been to provide an overview of the clinical trial landscape for Parkinson’s, particularly in the area of drug development. Such projects are difficult, however, as the landscape is broad and dynamic – lots of different approaches being applied and new entrants continually entering the arena.…
• Monthly Research Review – September 2019 September 30, 2019   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during September 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• A plutocratic proposal: iCancer February 2, 2020    Speeding up the clinical development process is a shared goal across many medical conditions (not just Parkinson’s and neurodegeneration), and there are many different approaches to achieving this that are being explored. Some of these approaches could be considered to be bordering on the unethical, but there are aspects of their structure and design that are still worthy of…
• The Wim Hof method February 6, 2020   A regular theme of the SoPD website is the reviewing of novel phamarcological treatments that are being tested on models of Parkinson’s. And while the breadth of the research is exciting and encouraging, the average reader may feel distant to the results of those studies as the experimental drug being tested is still a long way from possible regulatory…
• Is it time to back NAC? October 4, 2019   A lot of Parkinson’s research is focused on antioxidants – molecules that can reduce the level of stress a cell is under when it is not feeling well. One of the most widely discussed antioxidants on Parkinson’s online forums is a molecule called N–acetylcysteine (or NAC). Recently, the results of a small clinical trial – in which NAC was…
• Women with Depression and Anxiety Are Largest Parkinson’s Group with Fibromyalgia, Study Finds August 5, 2019 A distinct population of people are diagnosed with both Parkinson’s disease and fibromyalgia, a study in Israel found, noting they tend to be women with mental health issues, such as depression and anxiety, who rely on painkillers more than other Parkinson’s patients. The study, “Fibromyalgia-Like Syndrome Associated with Parkinson’s Disease—A Cohort Study,” was published in the Journal of Clinical Medicine. Fibromyalgia…